Results 111 to 120 of about 7,735 (172)

Early Bleeding Risk After DOAC Initiation With Concomitant Amiodarone in Older Adults With Atrial Fibrillation

Journal of Cardiovascular Electrophysiology, Volume 37, Issue 9, Page 2119-2121, September 2026.
ABSTRACT Background Amiodarone is frequently co‐prescribed with direct oral anticoagulants (DOACs) in atrial fibrillation (AF), but its impact on early bleeding risk after DOAC initiation in older adults remains uncertain. We evaluated short‐term safety outcomes associated with concomitant amiodarone use at the time of DOAC initiation.
Isadora D. Guarino, Saman Nazarian
wiley   +1 more source

Is Routine Interruption of Direct Oral Anticoagulants Necessary during Colorectal Endoscopic Mucosal Resection and Hot Snare Polypectomy? A Multicenter Propensity‐Matched Study

Journal of Gastroenterology and Hepatology, Volume 41, Issue 9, Page 2826-2833, September 2026.
ABSTRACT Background and Aims Colorectal endoscopic mucosal resection (EMR) and hot snare polypectomy (HSP) are high‐bleeding‐risk endoscopic procedures, and most clinical guidelines recommend stopping direct oral anticoagulants (DOACs) temporarily or switching to heparin‐bridging therapy (HBT). However, existing evidence is largely derived from cohorts
Yutaka Okagawa, Masanori Sato, Masahiro Hirakawa, Shogo Miura, Naotaka Hayasaka, Yusuke Tomita, Saki Ameda, Ginji Omori, Shutaro Oiwa, Akira Sakurada, Tomoyuki Abe, Shinya Minami, Tetsuya Sumiyoshi, Yasuhiro Nagaoka, Hiroyuki Hisai, Shinichi Katsuki, Kohichi Takada   +16 more
wiley   +1 more source

Dabigatran és paraproteinek együttes hatása a thrombin képződésre monoklonális gammopathiákban

Bevezetés: A bizonytalan jelentőségű monoklonális gammopathiát (MGUS) a kóros működésű plazmasejtek felszaporodása okozza. Az állapot kezelést nem igényel, azonban jelentősége, hogy malignus elváltozásba, myeloma multiplexbe (MM) alakulhat át.
Hrenkó, Mátyás
core  

Dabigatran effect on bacterial load.

, 2019
A significant reduction in the bacterial load were seen in valves (A), myocardium (B) and spleen (C) in dabigatran (10 mg/kg/b.i.d) compared to saline treated group.
Jens Peter Goetze (316975), Christian J. Lerche (5823854), Lars J. Christophersen (6616250), Kim Thomsen (6616256), Christian Enevold (235168), Niels Høiby (117862), Peter Ø. Jensen (679559), Claus Moser (321011), Pia R. Nielsen (6616253), Henning Bundgaard (441832)   +9 more
core   +1 more source

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients

, 2013
Christopher R Ellis, Daniel W KaiserVanderbilt Heart and Vascular Institute, Nashville, TN, USAAbstract: The use of novel oral anticoagulants (NOACs) for stroke and systemic embolism prevention in the setting of specifically non valvular atrial ...
Ellis CR, Kaiser DW
core  

Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report

International Journal of Emergency Medicine
Dabigatran is an oral anticoagulant that is mainly renally excreted. Despite its efficacy in preventing thromboembolic events, concerns arise regarding bleeding complications in patients with acute kidney injury. Idarucizumab is its specific antidote and
Rafik Matbouli, Olivier Pantet, Julien Castioni, Nima Vakilzadeh, Lorenzo Alberio, Olivier Hugli   +5 more
doaj   +1 more source

Dabigatran (October 2011)

Cleveland Clinic Journal of Medicine, 2012
Readers comment on the oral anticoagulant dabigatran (October 2011), and screening for cervical cancer (November 2011).
openaire   +2 more sources

Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile

Cost Effectiveness and Resource Allocation
Background Atrial fibrillation (AF) is the most common sustained arrhythmia in adults, associated with significant morbidity, mortality, and economic burden due to thromboembolic events.
Tomás Abbot, Nicolás Armijo, Luis Rojas Orellana, Andrés Giglio Jiménez, Carlos Balmaceda, Manuel Espinoza   +5 more
doaj   +1 more source

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal

, 2018
Marco Proietti,1–3 Giuseppe Boriani4 1Department of Neuroscience, IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy; 2Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK ...
Proietti M, Boriani G
core  

Dabigatran Reversal with Idarucizumab

New England Journal of Medicine, 2017
Pollack, Charles V., Reilly, Paul A, Weitz, Jeffrey I   +2 more
openaire   +6 more sources